AUROBAC THERAPEUTICS

About the Company

AUROBAC THERAPEUTICS is a biopharmaceutical company founded in 2022 by three highly renowned life sciences innovation companies, Boehringer Ingelheim, Evotec and bioMerieux, to develop the next generation of precision medicines to combat bacterial infections, Antimicrobial Resistance (AMR), and their consequences in acute care settings.
AUROBAC's R&D strategy addresses these unmet medical needs with patient- and pathogen-targeted programs designed to tackle both the causes and consequences of potentially life-threatening bacterial infections and AMR, including hospital-acquired and ventilator-associated bacterial pneumonia (HABP and VABP) and sepsis. Central to this approach is the adoption of innovative diagnostic strategies developed in partnership with bioMerieux, aimed at facilitating patient stratification and optimizing treatment outcomes.
AUROBAC THERAPEUTICS aims to cover the entire value chain of projects, including research and development, clinical trials, registration, and commercialization.